Sunday, 29 June

Program subject to change.

9:00 - 9:15 | Opening Welcome Remarks 

Welcome Remarks
EACPT2025 Chair Janne Backman, University of Helsinki, Helsinki, Finland, and
EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands
9:20 - 10:00 | Keynote Lecture 1

Chair: Janne Backman, University of Helsinki, Helsinki, Finland
The role of the European Medicines Agency in advancing science and innovation in Europe
Steffen Thirstrup, Chief Medical Officer, European Medicines Agency
10:00 - 10:30 | Refreshment Break

10:30 - 12:00 | Concurrent Sessions

Awards session (EPHAR/EACPT)
Co-Chairs: EACPT Chairperson Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands, EPHAR Chairperson Maria Jesus Sanz, University of Valencia, Valencia, Spain, and FSCP Chair Mikko Niemi, University of Helsinki, Helsinki, Finland

10:30 - 11:00EPHAR Award presentation - To be announced




11:00 - 11:30EACPT Award presentation - To be announced




11:30 - 12:00FSCP Awards and recognitions - To be announced




Session B1: Preclinical data informing clinical pharmacology 
Chairs: Mikko Koskinen, Orion Corporation, Espoo, Finland and Piet van der Graaf, Certara, Canterbury, United Kingdom

10:30 - 11:00QSP modelling - Speeding dose escalation trials in immuno-oncology 
Piet van der Graaf, Certara, Canterbury, United Kingdom




11:00 - 11:30Translational PKPD informing clinical dose selection
Pablo Morentin Gutierrez, AstraZeneca, Cambridge, United Kingdom




11:30 - 11:45Identifying Parkinson's disease-associated genes via a genome-wide association
study of Taiwanese population and a cell model (Abstract O001)
Ping Lin Tsai, National Cheng Kung University, Tainan, Taiwan




11:45 - 12:00In vivo assessment of MRP1 activity in murine and human skeletal muscle (Abstract O002)
Matthias Jackwerth, Medical University of Vienna, Vienna, Austria




Session C1: Therapeutic advances in the treatment of obesity
Chairs: Eriika Savontaus, University of Turku, Turku, Finland and Dominique Deplanque, University of Lille, Lille, France

10:30 - 11:00Next generation anti-obesity drugs
Christoffer Clemmensen, University of Copenhagen, Copenhagen, Denmark                     




11:00 - 11:30Pharmacovigilance of anti-obesity drugs
Jean-Luc Faillie, CHU de Montpellier, Montpellier, France




11:30 - 11:45Lingonberry supplementation induces anti-obesity and health-promoting effects 
on gut microbiome in high-fat diet-induced experimental obesity (Abstract O003)
Iiro Piippo, Tampere University, Tampere, Finland




11:45 - 12:00Effect of methylphenidate on BMI in children in relation to weight status (Abstract O004)
Jenny Kindblom, Sahlgrenska University Hospital, Gothenburg, Sweden



12:00 - 14:00 | Lunch and Poster Viewing


12:30 - 14:00Trainee poster award nominees present (posters A101-A120)










13:00 - 14:00Presenters at posters P201-P220, P301-P324, P401-413









14:00 - 15:30 | Concurrent Sessions

Session A1: Multiprofessional approach to pharmacotherapy
Chairs: Lasse Lehtonen, Helsinki University Hospital, Helsinki, Finland and Raisa Laaksonen, University of Helsinki, Helsinki, Finland

14:00 - 14:30Importance of clinical pharmacological and pharmaceutical care for medication safety
with oral antitumor therapy
Martin Fromm, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany

14:30 - 15:00Minimizing the risks in pharmacotherapy with medication review
Eva Sædder, Aarhus University Hospital, Denmark

15:00 - 15:15The tailored youngAMBORA care program during pediatric oral antitumor therapy solves
medication errors and improves satisfaction with information (Abstract O005)
Phyllis Lensker, Institute of Experimental and Clinical Pharmacology and Toxicology, 
Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany

15:15 - 15:30Drug-related problems from the pharmaceutical care perspective and the healthcare
perspective: an explorative analysis (Abstract O006)
Per Thysell, Sahlgrenska University Hospital, Gothenburg, Sweden

Session B2: Artificial intelligence in drug development
Chairs: Sammeli Liikkanen, Orion Corporation, Turku, Finland and Lauren Walker, University of Liverpool, Liverpool, United Kingdom

14:00 - 14:30Use of AI in the medication safety field
Lauren Walker, University of Liverpool, Liverpool, United Kingdom




14:30 - 15:00AI to reveal hidden biological mechanisms of disease and discover breakthrough
drugs by digital twins
Bruce Church, Aitia, Cambridge, Massachusetts, United States




15:00 - 15:15Drug-induced changes in gastrointestinal pacemaker activity may predict drug 
adverse reactions beyond the gut using a deep learning approach (Abstract O007)
Yuen Hang LIU, The Chinese University of Hong Kong, Hong Kong, Hong Kong




15:15 - 15:30How well can current decision support systems predict adverse drug events and can
predicts be improved using machine learning? (Abstract O008)
Marine L. Andersson, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden




Session C2: Immunopharmacology 
Chairs: Eeva Moilanen, Tampere University, Tampere, Finland and Joaquin S ez Pe ataro, Hospital Cl nic de Barcelona, Barcelona, Spain

14:00 - 14:30Novel insights in glucocorticoids
Karolien De Bosscher, UGent Department of Biomolecular Medicine, Ghent, Belgium            




14:30 - 15:00Transient Receptor Potential (TRP) cation channels
Zsuzsanna Helyes, Department of Pharmacology and Pharmacotherapy,
Medical School, University of Pécs, Pécs, Hungary




15:00 - 15:15Effect of severe renal function impairment on the single-dose pharmacokinetics,
pharmacodynamics, safety, and tolerability of cenerimod (Abstract O009)
Markus Stefan Mueller, Viatris Innovation GmbH, Allschwil, Switzerland




15:15 - 15:30The contact allergen methylisothiazolinone (MIT) is a potent activator of the TRPA1 ion
channel (Abstract O010)
Ilari Mäki-Opas, Tampere University, Tampere, Finland



15:30 - 16:00 | Refreshment Break
16:00 - 18:00 pm | Concurrent Sessions

Session A2: Education symposium 'Education pearls in CPT'
Chairs: Michiel van Agtmael, Amsterdam University Medical Center,  Amsterdam, the Netherlands and                              
Eriika Savontaus, University of Turku, Turku, Finland

16:00 - 16:15Team-based learning
Jitka Rychlíčková, Masaryk University, Brno, Czech Republic                                                          



16:15 - 16:30OSCE
Ellen van Leeuwen, Ghent University, Ghent, Begium



16:30 - 16:45Multiprofessional education
Karen Keijsers, Jeroen Bosch Hospital, Den Bosch, The Netherlands                   



16:45 - 17:00Flipped classroom
Emilio Sanz, Universidad de La Laguna, La Laguna, Spain



17:00 - 17:45Simulating prescribing in an acute situation
Students, Finland (coached by David Brinkman)



17:45 - 18:00Development of a drug list based on mechanisms of action and INN nomenclature for
undergraduate medical training (Abstract O011)
Alexander Oksche, Impp, Mainz, Germany



SSCPT Session B3: Cardiac toxicity
Chairs: Caroline Samer, Hôpitaux Universitaires de Genève, Geneva, Switzerland and Jérôme Bonzon, University Hospital Zurich, Zurich, Switzerland

16:00 - 16:25Clinical aspects of cardiotoxicity in the development of new drugs
Martin Bucher, University Hospital Zurich, Zurich, Switzerland



16:25 - 16:50The broad spectrum of drug induced cardiotoxicities
Francois Girardin, CHUV, Centre hospitalier universitaire Vaudois, Lausanne, Switzerland



16:50 - 17:15Epigenetic Rewiring in Doxorubicin-Induced Endotheliopathy
Shafeeq A. Mohammed, University of Zurich, Zurich, Switzerland


17:15 - 17:30Pharmacogenomics in prediction of cardiovascular drugs’ adverse reaction 
(PGx-CardioDrug) – data after 4 years (Abstract O012)
Livija Šimičević, University of Zagreb School of Medicine, Zagreb, Croatia



Industry Sponsored Talk by Celerion 

17:30 - 18:00          To waive or not to waive; Cardiac liability assessments in early drug development
                               Robert Lester, Celerion, Tempe, Arizona, United States
                               Caroline Engel, Celerion, Montreal, Quebec, Canada


EPHAR Session C3: RNA therapeutics
Chairs: Maria Jesus Sanz, University of Valencia, Valencia, Spain and Andreas Papapetropoulos, National and Kapodistrian University of Athens, Athens, Greece

16:00 - 16:30RNA therapeutics from theory to practice: an overview of mechanisms and approved drugs  
Andreas Papapetropoulos, National and Kapodistrian University of Athens, Athens, Greece



16:30 - 17:00Lessons from the development of miR125b*and miR450a for cardioprotection
Peter Ferdinandy, Semmelweis University, Budapest, Hungary



17:00 - 17:30We are formulators, how may we help?
Lea Ann Dailey, University of Vienna, Vienna, Austria



17:30 - 17:45Innovative therapeutic approaches for patients with hereditary transthyretin amyloidosis:
a cost-benefit analysis of switching from patisiran to vutrisiran (Abstract O013) 
Alessio Ardizzone, University of Messina, Messina, Italy



17:45 - 18:00Towards the fine understanding of local pharmacokinetics adopting integrative 
multiscale strategy (Abstract O014)
Florent Di Meo, Inserm U1248 P&t, Univ. Limoges, Limoges, France


17:30/18:00 - 18:30 | Exhibition Break
18:30 - 19:15 | EACPT Lifetime achievement award and lecture
Chair: EACPT Past-Chairman Pierre Marquet, University of Limoges, Limoges, France
Awardee to be announced
19:15 - 20:00 | Opening ceremony
20:00 - 21:00 | Reception (all attendees), followed by social event at Allas Pool (separate ticket required)
Small snacks available at the reception.